To Compare the Efficacy and Tolerability of A. Paniculata/A. Chilensis in Individuals With URTI
Status:
Recruiting
Trial end date:
2021-12-06
Target enrollment:
Participant gender:
Summary
Conventional therapy of upper respiratory tract infection (URTI) is not always effective and
sometimes leads to side effects and also to inappropriate use of antibiotic. Hence, a search
for safe and effective further treatment options is justified and would be a welcome addition
to available conventional treatment. Use of plant based dietary supplements has become
increasingly popular over the last few decades or so. Research based on some plants is more
than centuries old and its main therapeutic objective is to stimulate the self-healing power
of the body. Andrographolide was docked successfully in the binding site of SARS-CoV-2 Mpro.
Computational approaches also predicts this molecule to have good solubility,
pharmacodynamics property and target accuracy. This molecule also obeys Lipinski's rule,
which makes it a promising compound to pursue further biochemical and cell based assays to
explore its potential for use against COVID-19. A. Paniculata is a patented extract,
standardized to Andrographolide, 14-deoxyandrographolide, and Neo-andrographolide. Maqui
contains Maqui Berry Extract of Aristotelia Chilensis (10% Anthocyanidin, 8% Delphinidin)
belonging to the family of Elaeocarpaceae, which has been known for its use in several
conditions such as sore throat, fever and several other ailments. In the present study, the
therapeutic potential of Andrographis Paniculata and Aristotelia chilensis as single
ingredients as well as in combination will be evaluated in participants with common cold and
COVID related symptoms. The products to be evaluated have been rigorously standardized and
are available under the brand names of A. Paniculata and A. Chilensis. Literature indicates
that both A. Paniculata and A.Chilensis are effective and safe in the treatment of typical
cold-related symptoms in adults.